An anti-RSV antibody or antigen-binding fragment thereof, wherein: RSV does not produce a virus that escapes neutralization by the antibody or antigen-binding fragment thereof after more than 10 or more rounds of viral replication in the presence of the antibody or antigen-binding fragment thereof, wherein: the antibody or antigen-binding fragment comprises: a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:405 a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 406; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:407; and a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 408; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:409; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:410; and the antibody or antigen-binding fragment thereof immunospecifically binds to Respiratory Syncytial Virus fusion protein and/or neutralizes RSV. RSV does not produce a virus that escapes neutralization by the antibody or antigen-binding fragment thereof after more than 10 or more rounds of viral replication in the presence of the antibody or antigen-binding fragment thereof, wherein: the antibody or antigen-binding fragment comprises: a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:405 a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 406; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:407; and a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 408; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:409; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:410; and the antibody or antigen-binding fragment thereof immunospecifically binds to Respiratory Syncytial Virus fusion protein and/or neutralizes RSV. the antibody or antigen-binding fragment comprises: a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:405 a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 406; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:407; and a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 408; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:409; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:410; and a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:405 a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 406; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:407; and a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 408; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:409; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:410; and the antibody or antigen-binding fragment thereof immunospecifically binds to Respiratory Syncytial Virus fusion protein and/or neutralizes RSV.